Navigation Links
FDA approves drug for rare liver disease

Hereditary tyrosinemia type 1( HT-1) is a genetic metabolic disorder that causes progressive liver failure and liver cancer in young children. It's a very rare disease.// It is not among the metabolic diseases that all newborns are tested for at birth, so often infants die undiagnosed. This is an absolutely fatal disease until now.

Children born with such a very rare but very lethal liver disease have won the first drug that promises to help them live years longer. The drug, named Orfadin, amazingly is a failed weed killer that Swedish scientists discovered could fight a disease called hereditary tyrosinemia.

"This is a real breakthrough drug," said Dr. Marlene Haffner of the U.S. Food and Drug Administration. She said scientists once referred to the drug as "Lazarene, because these kids were so sick and then they were well."

For babies who are diagnosed, the only treatment is a special low-protein diet. Orfadin may significantly improve those dismal statistics. It works by blocking formation of the liver-destroying toxins. The drug's cost depends on the dose, which varies with the child's size: $12,000 a year for an infant, up to $60,000 a year for an older child.
'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves first pocket-sized EKG machine
4. FDA approves Watson Pharmaceuticals Oxytrol patch
5. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
6. Madras High Court Disapproves of Comparative Advertisements
7. FDA approves Phase 0 trial which tests experimental drugs on humans
8. FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology: